Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist
Min Jin Lee, Bo Seong Yun, Seok Ju Seong, Mi-La Kim, Yong Wook Jung, Mi Kyoung Kim, Hyo Sook Bae, Da Hee Kim, Ji Young Hwang
Obstet Gynecol Sci. 2017;60(1):69-73.   Published online 2017 Jan 19     DOI: https://doi.org/10.5468/ogs.2017.60.1.69
Citations to this article as recorded by Crossref logo
What happens after randomised controlled trials? Uterine fibroids and ulipristal acetate: systematic review and meta-analysis of "real-world" data
Neha Shah, Elizabeth Egbase, Michael Sideris, Funlayo Odejinmi
Archives of Gynecology and Obstetrics.2021; 303(5): 1121.     CrossRef
Effect of Perioperative Transfusion on Postoperative Morbidity Following Minimally Invasive Hysterectomy for Benign Indications
Paul Tyan, Ali Taher, Erin Carey, Richard Amdur, Cole Messersmith, Hannah N. Robinson, Alex Gu, Maria V. Vargas, Gaby N. Moawad
Journal of Minimally Invasive Gynecology.2020; 27(1): 200.     CrossRef
Differences in fibroid vascularity after three months of pre-treatment with leuprolide acetate or ulipristal acetate: A pilot study
Marissa Frijlingh, Inge De Milliano, Wouter. J.K. Hehenkamp, Judith. A.F. Huirne
European Journal of Obstetrics & Gynecology and Reproductive Biology.2020; 245: 186.     CrossRef
First Impressions Can Be Deceiving: Surgical Outcomes of Laparoscopic Myomectomy in Patients Pretreated with Ulipristal Acetate
Clarissa Frascà, Alessandro Arena, Eugenia Degli Esposti, Diego Raimondo, Simona Del Forno, Elisa Moro, Margherita Zanello, Mohamed Mabrouk, Renato Seracchioli
Journal of Minimally Invasive Gynecology.2020; 27(3): 633.     CrossRef
Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids
Iwona Szydłowska, Aleksandra Marciniak, Jolanta Nawrocka-Rutkowska, Aleksandra Rył, Andrzej Starczewski
International Journal of Environmental Research and Public Health.2020; 17(3): 798.     CrossRef
Predictors of uterine fibroid volume reduction under ulipristal acetate: a prospective MRI study
Antoine Netter, Vanessa Pauly, Pascale Siles, Audrey Pivano, Vincent Vidal, Aubert Agostini
Reproductive BioMedicine Online.2019; 39(5): 795.     CrossRef
Potential synergism between ulipristal acetate and vitamin D3 in uterine fibroid pharmacotherapy – 2 case studies
Michał Ciebiera, Błażej Męczekalski, Krzysztof Łukaszuk, Grzegorz Jakiel
Gynecological Endocrinology.2019; 35(6): 473.     CrossRef
Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate
Bo Seong Yun, Seok Ju Seong, Yong Wook Jung, Mi-La Kim, Hyo Sook Bae, Mi Kyoung Kim, Sung Shin Shim
European Journal of Obstetrics & Gynecology and Reproductive Biology.2018; 224: 133.     CrossRef
Is ulipristal acetate the new drug of choice for the medical management of uterine fibroids? Res ipsa loquitur?
Funlayo Odejinmi, Reeba Oliver, Rebecca Mallick
Women's Health.2017; 13(3): 98.     CrossRef
Medical Management of Symptomatic Fibroids: Worth It?
Chandrashekhar V. Hegde
The Journal of Obstetrics and Gynecology of India.2017; 67(4): 233.     CrossRef